Brain drug delivery system: An overview

Current Drug Therapy

Volumn 5, Issue 2, 2010, Pages 105-110

  Ligade, Pushpanjali C ^a   Jadhav, Kisan R ^a   Kadam, Vilasrao J ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

Brain targeting technology; Colloidal drug carriers; Liposomes; Micelles; Nano technology

Indexed keywords

DRUG CARRIER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN P; IRON OXIDE; LEUCINE ENKEPHALIN; LIPOSOME; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOTOFRIN; RADIOPHARMACEUTICAL AGENT; RIFAMPICIN; STREPTAVIDIN;

BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; COLLOID; DEGENERATIVE DISEASE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCEPHALITIS; HUMAN; MICELLE; NANOTECHNOLOGY; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 77951615520     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488510791065085     Document Type: Review

References (53)

1. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1-20. (Pubitemid 32144788)
2. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems:an overview. Eur J Pharm Biopharm 2004; 58: 445-455
3. Bae Y, Fukushima S, Harada A, et al. Design of environmentsensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed 2003; 42: 4640-4643 (Pubitemid 37271305)
4. Torchilin VP. Structure and design of polymeric surfactant- based drug delivery system. J Control Release 2003; 73: 137-172
5. Haag R. Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angew Chem Int Ed 2004; 43: 278-282 (Pubitemid 38090059)
6. Vandermeulen GWM, Klok HA. Peptide/Protein hybrid material: enhanced control of structure and improved performance through conjugation of biological and synthetic polymers. Macromol Biosci 2003; 4: 383-398
7. Charman WN, Chan HK, Finnin BC, et al. Drug delivery: a key factor in realising the full therapeutic potential of drugs. Drug Dev Res 1999; 46: 316-327
8. Byrne ME, Park K, Peppas NA. Molecular imprinting within hydrogels. Adv Drug Deliv Rev 2002; 54: 149-161
9. Rosler A, Vandermeulen GWM, Klok HA. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2001; 53: 95-108.
10. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004; 56: 3-17.
11. Landau AJ, Eberhardt RT, Frishman WH. Intranasal delivery of cardiovascular agents: An innovative approach to cardiovascular pharmacotherapy. Am Heart J 1994; 127: 1594-1599
12. Yamada T. The potential of the nasal mucosa route for emergency drug administration via a high-pressure needleless injection system. Anesthesia Progress 2004; 51: 6-61.
13. Chieny W, Su KSE, Chang SF. Nasal systemic drug delivery. Drugs and the pharmaceutical sciences 1989; New York, Marcel Dekker, Inc.
14. Muller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharmac 2004; 58: 343-356
15. Cruz E, Carvalheiro M, Jorge J, et al. Parasitologia 2005; 47 (Suppl.1): 81.
16. th Liposomes Advances, Progress in Drug and Vaccine Delivery,Londres, Inglaterra 2005; p. 50.
17. Alvarez-Lorenzo C, Concheiro A. Molecular imprinted polymers for drug delivery. J Chromatogr B 2004; 804: 231-245 (Pubitemid 38469889)
18. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003; 255: 13-32. (Pubitemid 36369587)
19. Winterhalter M, Hilty C, Bezrukov SM, et al. Controlling membrane permeability with bacterialporins: applications to encapsulated enzymes. Talanta 2001; 55: 965-971 (Pubitemid 33095484)
20. Gaspar MM, Neves S, Portaels F, Pedrosa J, Silva MT, Cruz ME. Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection. Antimicrob Agents Chemother 2000; 44(9): 2424-2430 (Pubitemid 30650890)
21. Cruz MEM, Gaspar MM, Lopes F, et al. Liposomal Lasparaginase: in vivo evaluation. Int J Pharm 1993; 96: 67-77.
22. Gaspar MM, Perez Soler R, Cruz MEM. Biological characterization of L-asparaginase liposomal formulations. Cancer Chemother Pharmacol 1996; 38: 373-377 (Pubitemid 26226304)
23. Corvo ML, Jorge JC, van't Hof R, et al. Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochim Biophys Acta 2002; 1564: 227-236
24. Cruz MEM, Gaspar MM, Martins MB, et al. In: Duzgunes N. Ed. Methods in Enzymology, Liposomes, Part E, Elsevier Academic Press, Amsterdam 2005; vol.391, pp. 395-413.
25. http://www.avantilipids.com/Liposomes.asp [Accessed in May 2009].
26. http://www.avantilipids.com/preparationofliposomes.html [Accessed in May 2009].
27. http://www.avantilipids.com/preparationofmultilemellarliposomes.html [Accessed in May 2009].
28. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan based micro and nanoparticles in drug delivery. J Control Release 2004; 100: 5-28. (Pubitemid 39445982)
29. Sood A, Panchagnula R. Parenteral Route: an opportunity for protein and peptide drug delivery. Chem Rev 2000; 101: 3275-3303
30. Green NM. Avidin. Adv Protein Chem 1975; 29: 85-133.
31. Kurihara A, Deguchi Y, Pardridge WM. Epidermal growth factor radiopharmaceuticals: 111 In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug Chem 1999; 10: 502-511 (Pubitemid 29062515)
32. Kurihara A, Pardridge WM. A-1-40 peptide radiopharmaceuticals for brain amyloid imaging: 111 In chelation, conjugation to polyethyleneglycol-biotin linkers, and autoradiography with Alzheimer's disease brain sections. Bioconjug Chem 2000; 11: 380-386 (Pubitemid 30324904)
33. Kurihara A, Pardridge WM. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res 1999; 54: 6159-6163 (Pubitemid 30035637)
34. Zhang Y, Pardridge WM. Neuroprotection in transient focal brain ischemia following delayed, intravenous administration of BDNF conjugated to a blood-brain barrier drug targeting system. Stroke 2001; 32: 1378-1384 (Pubitemid 32146264)
35. Pardridge WM. Neuroprotection in stroke: is it time to consider large-molecule drugs. Drug Discovery Today 2001; 6: 751-753
36. Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res 2001; 889: 49-56. (Pubitemid 32146264)
37. Wu D, Pardridge WM. Neuroprotection with non-invasive neurotrophin delivery to brain. Proc Natl Acad Sci USA 1999; 96: 254-259 (Pubitemid 29036086)
38. Sakane T, Pardridge WM. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm Res 1997; 14: 1085-1091 (Pubitemid 27371411)
39. Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res 1998; 15: 576-582 (Pubitemid 28214951)
40. Costantino HR, Lisbeth I, Brandt G, et al. Intranasal delivery-Physicochemical and therapeutic aspects. Int J Pharm 2007; 337: 1-24.
41. Jackson RT, Tigges J, Arnold W. Subarachnoid space of the CNS, nasal mucosa and lymphatic system. Arch Otolaryngol 1979; 105: 180-184 (Pubitemid 9149116)
42. Faber WM. The nasal mucosa and the subarachnoid space. Am J Anat 1937; 62: 121-148
43. Yoffey JM. Passage of fluid and other substances through the nasal mucosa. J Laryngol Otol 1958; 72: 377-383
44. Vyas TK, Salphati I, Benet LZ. Intranasal drug delivery for brain targeting .Curr Drug Deliv 2005; 2: 165-175
45. SantiniJr JT, Richards AC, Scheidt R, et al. Microchips as controlled drug-delivery devices. Angew Chem Int Ed 2000; 39: 2396-2407
46. Kopecek J. Smart and genetically engineered biomaterials and drug delivery systems. Eur J Pharm Sci 2003; 20: 1-16. (Pubitemid 37103227)
47. Niculescu Duvaz I, Springer CJ. Antibody directed enzyme prodrug therapy (ADEPT): a review. Adv Drug Deliv Rev 1997; 26: 151-172 (Pubitemid 27289531)
48. Stiles CD. Cancer of the central nervous system. Biochim Biophys Acta 1998; 1377: R1-R10.
49. Pardridge WM. Brain drug targeting: The future of brain drug development. Cambridge, England: Cambridge University Press 2001; 1-353.
50. Manabe T, Okino H, Maeyama R, et al. Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: trans-tissue, sustained local drug-delivery systems. J Control Release 2004; 100: 317-330 (Pubitemid 39572915)
51. Pardridge WM. BBB-genomics: creating new openings for braindrug targeting. Drug Discov Today 2001; 6: 381-383
52. Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987; 84: 6899-6903
53. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91: 7727-7731 (Pubitemid 24238258)